Science and Research

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC.

Study details
Study-ID: NCT04746924, 2020-004985-21
Study-ID: NCT04746924, 2020-004985-21
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center, DZL on steering board
DZL Role: DZL recruiting center, DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: ARCN, UGMLC
DZL Participating Sites: ARCN, UGMLC
Start Date: 08.06.2021
Completion Date: 31.03.2026
Status: Active / not recruiting
Status: Active / not recruiting
DZL recruiting center, DZL on steering board
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.